|
Baseline
|
After 8–10# CRT
|
% Change
|
---|
Patient
|
pTRG
|
Stage
|
Clinical
|
Tumour
|
Muscle
|
T:M
|
Tumour
|
Tumour
|
% of
|
Tumour
|
Muscle
|
T:M
|
Tumour
|
Tumour
|
% of
|
Tumour
|
Muscle
|
T:M
|
Tumour
|
Tumour
|
% of
|
---|
Number
|
AJCC
| |
Response
|
SUV
|
SUV
|
SUV
|
hypoxic
|
ROI
|
tumour
|
SUV
|
SUV
|
SUV
|
hypoxic
|
ROI
|
tumour
|
SUV
|
SUV
|
SUV
|
hypoxic
|
ROI
|
tumour
|
---|
| | | |
max
|
max
|
max
|
volume
|
volume
|
volume
|
max
|
max
|
max
|
volume
|
volume
|
volume
|
max
|
max
|
max
|
volume
|
volume
|
volume
|
---|
| | | | | | |
cm3
|
cm3
|
i.e. hypoxic
| | | |
cm3
|
cm3
|
i.e. hypoxic
| | | | | |
i.e. hypoxic
|
---|
P1
|
1
|
ypT3N2
|
Poor
|
2.09
|
1.54
|
1.35
|
0.05
|
80.41
|
0.06
|
1.79
|
1.32
|
1.36
|
0.15
|
88.60
|
0.17
|
−14.35
|
−14.50
|
0.17
|
199.99
|
10.19
|
172.26
|
P2
|
1
|
ypT3N1
|
Good
|
5.19
|
2.30
|
2.26
|
1.93
|
23.20
|
8.32
|
4.97
|
1.73
|
2.87
|
2.93
|
26.85
|
10.93
|
−4.31
|
−24.68
|
27.05
|
51.90
|
15.70
|
31.28
|
P3
|
3
|
ypT3N0
|
Poor
|
3.39
|
1.95
|
1.74
|
0.98
|
179.77
|
0.54
|
2.24
|
1.93
|
1.16
|
0.00
|
86.53
|
0.00
|
−33.86
|
−1.00
|
−33.19
|
−100.00
|
−51.87
|
−100.00
|
P4
|
2
|
ypT3N0
|
Poor
|
4.16
|
1.74
|
2.39
|
4.03
|
30.66
|
13.16
|
2.70
|
1.84
|
1.47
|
0.20
|
13.35
|
1.47
|
−35.10
|
5.79
|
−38.65
|
−95.15
|
−56.46
|
−88.86
|
P5
|
NR
|
N/A
|
Good
|
4.98
|
1.93
|
2.58
|
3.18
|
62.59
|
5.08
|
1.78
|
1.68
|
1.06
|
0.00
|
55.79
|
0.00
|
−64.17
|
−12.69
|
−58.96
|
−100.00
|
−10.86
|
−100.00
|
P6
|
NR
|
N/A
|
Poor
|
3.38
|
2.03
|
1.66
|
0.81
|
18.80
|
4.29
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
P7
|
NR
|
N/A
|
Good
|
3.52
|
1.62
|
2.17
|
0.39
|
4.16
|
9.41
|
2.44
|
1.51
|
1.62
|
0.12
|
0.93
|
13.16
|
−30.54
|
−6.85
|
−25.43
|
−68.75
|
−77.65
|
39.80
|
P8
|
2
|
ypT3N2
|
Poor
|
5.31
|
2.35
|
2.27
|
1.17
|
28.43
|
4.13
|
2.49
|
1.95
|
1.27
|
0.00
|
28.61
|
0.00
|
−53.22
|
−16.71
|
−43.84
|
−100.00
|
0.60
|
−100.00
|
P9
|
2
|
ypT3N1
|
Poor
|
3.04
|
1.45
|
2.10
|
1.44
|
15.06
|
9.58
|
1.82
|
1.41
|
1.30
|
0.00
|
13.96
|
0.00
|
−39.97
|
−2.59
|
−38.37
|
−100.00
|
−7.31
|
−100.00
|
P10
|
0
|
ypT0N1
|
Good
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
P11
|
2
|
ypT3N0
|
Good*
|
1.94
|
1.74
|
1.11
|
0.00
|
10.98
|
0.00
|
2.40
|
1.88
|
1.27
|
0.00
|
5.23
|
0.00
|
23.87
|
8.16
|
14.52
|
0.00
|
−52.34
|
0.00
|
Median
| | | |
3.46
|
1.83
|
2.14
|
1.08
|
25.82
|
4.68
|
2.40
|
1.73
|
1.30
|
0.00
|
26.85
|
0.00
|
−33.86
|
−6.85
|
−33.19
|
−95.15
|
−10.86
|
−88.86
|
IQR
| | | |
1.65
|
0.36
|
0.58
|
1.31
|
38.61
|
7.70
|
0.66
|
0.37
|
0.19
|
0.15
|
42.44
|
1.47
|
25.62
|
13.49
|
38.81
|
100.00
|
52.94
|
131.28
|
- Response as defined in Table 1
-
[
18
F]FMISO [18F]fluoromisonidazole, PET positron emission tomography, SUV standardised uptake value, T:M tumour to muscle ratio, max maximum, % percentage, CRT chemoradiotherapy, IQR interquartile range, i.e. that is, ROI region of interest, NR No resection, N/A not applicable, cm
3 cubic centimetre, h hour, *Delayed surgery due to initial good response, clinical outcome used; TRG tumour regression grade, AJCC American Joint Committee on Cancer